Express Pharma
NOVEMBER 28, 2024
However, winning in the Indian market requires a strategically thought-out India-specific strategy that accounts for the market nuances such as non-uniform payer coverage of specialty drugs, pricing schedules and varying levels of healthcare infrastructure.
Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 12, 2024
They said they recently completed a pharmacokinetics study — tracking how a drug behaves in the body — that gave them confidence to advance the molecule. They will present that data next year. The PrEP has been available for a decade in the form of a daily pill.
pharmaphorum
JUNE 12, 2025
Importantly, this type of insight also supports smarter negotiations around drug pricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.
Pharmacy Times
JUNE 23, 2025
This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. If the request doesn’t come in, all 505(b)(2) drugs will be considered nontherapeutically equivalent and therefore get their own J-code.
Pharmaceutical Commerce
JUNE 17, 2025
Artificial intelligence (AI) presents a transformative opportunity to address these challenges and enhance HTA methodologies while ensuring more informed formulary decisions and efficient allocation of healthcare resources.
PharmaVoice
JUNE 16, 2025
Known as the negotiators between health plans, pharmacies and drug companies, pharmacy benefit managers are currently entangled in a national conversation about reform. The pharma industry has long blamed PBMs for rising drug prices, pointing to opaque rebate and profit structures , and proposed policy shifts could take them to task.
Expert insights. Personalized for you.
105 
Let's personalize your content